GH Research PLC (GHRS) IPO Opens 38% Higher

Today's IPO for GH Research PLC (NASDAQ: GHRS) opened for trading at $22 after pricing 10,000,000 ordinary shares at an initial public offering price of $16 per share.

Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.

You May Also Be Interested In

• Varsal files for IPO on NYSE American with ticker VAT
• Verizon falls 7%, AT&T hits 52-week low as SpaceX and cable rivals converge
• Nasdaq reports record $129.3B raised in first half of 2026